Klinikum Dortmund

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors (2024) Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, et al. Journal article S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion (2024) Groß S, Bitzer M, Albert J, Blödt S, Boda-Heggemann J, Brunner T, Caspari R, et al. Journal article Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid (2024) Kramer N, Müller G, Zierold S, Röckel M, Fröhlich W, Schefzyk M, Kumbrink J, et al. Journal article, Letter S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma“ – update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention (2023) Leiter U, Heppt M, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care (2023) Heppt M, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article S3-Leitlinie “Aktinische Keratose und Plattenepithelkarzinom der Haut“ – Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen (2023) Heppt M, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, et al. Journal article Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study (2023) Lodde GC, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Hauschild A, et al. Journal article S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion (2023) Bitzer M, Groß S, Albert J, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, et al. Journal article ETOPOSIDE FOR PRIMARY HLH - BETTER THAN ITS REPUTATION (2023) Lehmberg K, Ledig S, Wustrau K, Kontny U, Westphal S, Hundsdoerfer P, Jorch N, et al. Conference contribution Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study (2022) Thiem A, Mashhadiakbar P, Cussigh C, Hassel JC, Grimmelmann I, Gutzmer R, Schlaak M, et al. Journal article